Viewing Study NCT00716456

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:32 PM
Ignite Modification Date: 2026-02-22 @ 9:04 AM
Study NCT ID: NCT00716456
Status: COMPLETED
Last Update Posted: 2015-04-30
First Post: 2008-07-15
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None MAB C225(CETUXIMAB)(ANTI-EGFR) View
None OSI-774, TARCEVA (ERLOTINIB) View
None Lung View
None Adenocarcinoma View
None Lung cancer View